Key Facts & Figures
Roche Group
Results 2009
- Group sales increase by 10% to 49.1 billion Swiss francs (in local currencies; 8% in Swiss francs; 7% in US dollars).
- Operating profit before exceptional items increases by 14% (8% in Swiss francs) to 15.0 billion Swiss francs due to strong sales growth and continuing productivity improvements.
- Net income of 8.5 billion Swiss francs, down by 22% compared with the previous year due to exceptional items relating to the Genentech transaction and integration.
- Core EPS at constant exchange rates 20% above 2008 (10% in Swiss francs).
Pharmaceuticals
Results 2009
- Pharmaceuticals sales grow by 11% — almost twice the global market growth rate
- Tamiflu sales grow sharply to 3.2 billion Swiss francs following substantially increased demand during the pandemic influenza A(H1N1) virus (‘swine flu’) outbreak.
- Operating profit margin before exceptional items increases 1.2 percentage points at constant exchange rates.
- Strong R&D pipeline with ten new molecular entities in late-stage clinical testing; six new compounds entered phase III clinical trials in 2009.
- Actemra approved in US for treatment of rheumatoid arthritis in January 2010.
Diagnostics
Results 2009
- Sales increase by 9% (4% in Swiss francs and 4% in US dollars) to 10.1 billion Swiss francs — more than twice the market growth rate.
- Operating profit margin at constant exchange rates increases 0.4 percentage points (–0.4 percentage points in Swiss francs).
